NEW YORK (GenomeWeb News) – Qiagen this week said that it has completed European certification for its careHPV test, which will be used in low-resource, developing countries that recognize the CE mark. The test can be performed in a community facility without mains electricity or running water and offers HPV detection results in a matter of hours, said Qiagen.
The firm also said that it will pursue World Health Organization prequalification — an approval process that allows United Nations agencies to purchase diagnostic technologies for low-income countries. In addition, Qiagen is preparing the submission of its careHPV marketing application to the Chinese State Food & Drug Association.
The European Commission this week cleared Merck KGaA's $7.2 billion agreement to acquire Millipore. The firms expect to close the deal next week.
Pacific Biosciences today launched a software developer' network, called PacBio DevNet, which is intended to support academic informatics developers, life scientists, and independent software vendors interested in creating tools to work with the firm's sequencing data.
Miraculins this week said that it has granted an aggregate of 1,850,000 stock options at an exercise price of C$0.14 (US$.14) per common share to President and CEO Christopher Moreau, a consultant, and certain directors of the firm.
iKaryos Diagnostics this week announced that it has signed up regional distributors to offer its cancer diagnostic services, using the firm's SNP array Virtual Karyoptyes, in Australia, Egypt, Hong Kong, Korea, Kuwait, Saudi Arabia, Singapore, and United Arab Emirates. It did not disclose the names of the distributors.